NAD+: The Energy Currency Whose Decline Defines Metabolic Aging

The short version

NAD+ stands for Nicotinamide Adenine Dinucleotide, and it sits at the center of almost every energy-producing reaction in the cell. It works by carrying electrons: in its oxidized form (NAD+) it accepts electrons; in its reduced form (NADH) it donates them, driving the mitochondrial machinery that makes ATP. But it also does something else — it is consumed by signaling enzymes called sirtuins and PARPs that govern DNA repair, inflammation, and gene regulation ^[4].

Here is the key aging story. Tissue NAD+ levels fall with age, partly because an enzyme called CD38 rises with age and burns through the NAD+ pool ^[6]. Researchers have tried to reverse that decline by supplying precursors — chiefly NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — that the body converts to NAD+. Human trials consistently raise blood NAD+. But a 2025 review in Nature Metabolism concluded that human data show limited efficacy for hard clinical endpoints, that age-related tissue NAD+ decline has been confirmed in only a limited number of human studies, and that far more clinical work is needed ^[1].

NAD+ and its precursors are sold as dietary supplements, not approved drugs. IV NAD+ wellness therapy is separately marketed with minimal controlled evidence and has been subject to safety warnings. This page summarizes the research; it does not recommend any product or dose.

What it is

NAD+ is a dinucleotide — two nucleotides linked by two bridging phosphate groups. One nucleotide carries a nicotinamide (vitamin B3 derivative) ring; the other carries adenine. The molecular formula is C21H27N7O14P2. Its oxidized form is NAD+; its reduced form, NADH, carries an additional hydride ion. The cell maintains both forms and the NAD+/NADH ratio is a read-out of metabolic state.

NAD+ is not a peptide. It is an endogenous metabolite produced via three biosynthetic routes: the Preiss-Handler pathway from nicotinic acid, the de-novo pathway from tryptophan, and the salvage pathway from nicotinamide via the rate-limiting enzyme NAMPT. The precursors NMN and NR feed into the salvage pathway and are the forms most commonly used in human supplementation studies.

How it works

NAD+ serves two distinct cellular roles. As a redox carrier, it shuttles electrons through glycolysis, the TCA cycle (Krebs cycle), and oxidative phosphorylation at the inner mitochondrial membrane, where the electron transport chain regenerates ATP. In this role, NAD+ is continuously recycled between its oxidized and reduced forms.

As a signaling substrate, it is irreversibly consumed. The three main consuming enzyme families compete for the same NAD+ pool ^[4]:

• Sirtuins (SIRT1-SIRT7) — NAD+-dependent deacylases that regulate gene expression, mitochondrial biogenesis, and stress responses. Sirtuin activity falls as NAD+ declines with age.
• PARPs (primarily PARP1) — Poly(ADP-ribose) polymerases that detect and respond to DNA strand breaks; massive activation during genotoxic stress can catastrophically deplete the NAD+ pool.
• CD38/CD157 — Ectoenzymes on immune and other cells. CD38 activity rises with age and is the principal driver of the age-related NAD+ fall; mice lacking CD38 maintain NAD+ and show better metabolic function as they age ^[6].

In a 2025 Circulation Research study using human myocardium and a murine heart-failure model (HFpEF), NAD+ repletion restored the cardiac ketogenic enzyme HMGCS2 via sirtuin-mediated deacetylation, increased fatty-acid oxidation, and rescued cardiac function — an HMGCS2-dependent effect ^[7]. This illustrates how NAD+ restoration can act through specific downstream enzyme targets rather than through a single unified mechanism.

What the research shows

Foundational biology. A 2021 Nature Reviews Molecular Cell Biology review framed the central story: tissue NAD+ declines with age across model organisms and humans, primarily because sirtuins, PARPs, and CD38 compete for the NAD+ pool; restoring NAD+ is a candidate strategy against age-related metabolic disease ^[4].

Age-related decline mechanism. CD38 was established as the dominant driver of the age-related NAD+ fall in a 2016 Cell Metabolism study: CD38 knockout mice maintain NAD+ levels and SIRT3 activity, and show improved mitochondrial function and metabolic health as they age ^[6].

NMN human RCT. In a multicenter, double-blind, placebo-controlled dose-ranging trial in middle-aged adults, oral NMN at 300, 600, and 900 mg/day for 60 days raised blood NAD+ dose-dependently at both 30 and 60 days (p≤0.001 vs placebo across all doses), improved walking distance and quality-of-life scores, and identified 600 mg/day as optimal; no safety concerns at any dose ^[2].

NMN muscle insulin sensitivity. In prediabetic postmenopausal women, 10 weeks of oral NMN at 250 mg/day improved skeletal-muscle insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp — the most rigorous metabolic measurement available — though body composition and HbA1c did not change ^[3].

NR dose-response. Oral NR at 100, 300, or 1,000 mg/day for 8 weeks raised whole-blood NAD+ by 22%, 51%, and 142% respectively in healthy overweight adults in a double-blind RCT; no flushing and no significant adverse-event differences from placebo at any dose ^[5].

Current state of human evidence. A 2025 Nature Metabolism review — the most current authoritative synthesis — concluded that human trials with NAD+ precursors have shown limited clinical efficacy, that age-related NAD+ decline has been consistently confirmed in only a limited number of human studies, and that tissue-specific NAD+ dynamics remain poorly characterized; the review calls for more rigorous systemic and tissue-specific clinical work rather than continued reliance on rodent extrapolation ^[1].

Cardiac application. In a 2025 Circulation Research study, NAD+ repletion rescued cardiac function in HFpEF via an HMGCS2-ketogenic mechanism — providing mechanistic depth for an NAD+ action pathway that goes beyond sirtuin activation ^[7].

Reported effects, cautions & safety

The safety picture for oral NMN and NR is reassuring within the window of completed trials — both precursors are well tolerated at doses up to 1,000 mg/day over periods of 8-10 weeks, with no significant adverse events in controlled studies ^[2][5]. However, several cautions are documented in the literature:

• Limited clinical-endpoint evidence. Blood NAD+ elevation is consistent and robust; translation to hard clinical outcomes (disease prevention, longevity) in humans is not yet established. The 2025 Nature Metabolism review is explicit on this point ^[1].
• Oral NAD+ vs precursors. Oral NAD+ itself is poorly absorbed intact by cells; most researchers consider NMN or NR the rational oral approach. Products marketed simply as "NAD+" capsules may deliver little measurable benefit.
• IV NAD+ risks. IV NAD+ wellness therapy is widely offered but rests on minimal controlled evidence. Infused NAD+ is rapidly cleared from plasma, and infusions delivered too fast cause chest discomfort, flushing, and nausea. A compounded injectable NAD+ product was subject to a Class I FDA recall for elevated bacterial endotoxin.
• Theoretical cancer concern. NAD+ supports rapidly dividing cells; a theoretical concern exists that boosting NAD+ could accelerate existing cancer metabolism. Evidence is context-dependent, and caution is appropriate for cancer populations.
• NMN regulatory uncertainty. The FDA has taken the position that NMN may be excluded from the dietary-supplement definition because it was investigated as a drug before being marketed as a supplement — a status still being resolved.
• Product quality. Supplement-grade NAD+ precursors vary widely in purity and actual content; third-party testing is not guaranteed.

No community-anecdote reports are compiled in this desk's source material for NAD+, so none are presented here; the cautions above are drawn from the cited literature.

Where it fits in longevity and cellular-energetics research

NAD+ is the lead molecule on this desk and the one with the strongest human evidence — but that evidence base still has a significant gap between measuring blood NAD+ and demonstrating clinical benefit. NMN and NR are the best-validated precursors in human trials ^[2][3][5]. The 2025 reviews ^[1] and the cardiac work ^[7] together suggest NAD+ biology is mechanistically rich but clinically early, especially for longevity claims. Read alongside MOTS-c, which approaches mitochondrial aging from the signaling side rather than the substrate side, NAD+ illustrates how the same organelle can be studied from very different angles. See the comparison page for how the two line up.